Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease
Research article
[키워드] Admission
Anticoagulants
approach
ARDSsevere acute respiratory distress syndrome
Biomarkers
C-reactive protein
CBCcomplete blood count
chronic disease
Chronic diseases
complete blood count
control group
Coronavirus disease 2019
Corticosteroid
COVID-19
COVID-19 patient
COVID-19coronavirus disease 2019
CRP
CRP level
CRPC-reactive protein
Dexamethasone
diagnostic
effective
Effectiveness
groups
hematological
hematological parameter
identify
Impact
lab
material
mortality rate
neutrophil count
novel coronavirus disease
Patient
patients treated
protocol
protocols
Result
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
severe acute respiratory distress syndrome
severe acute respiratory syndrome coronavirus 2
severity
significantly
standard treatment
statistically significant
therapeutic
Tocilizumab
treated
treating COVID-19 patient
Treatment
Treatment protocol
was performed
WBC
[DOI] 10.1016/j.medcli.2022.02.013 [Article Type] Research article
[DOI] 10.1016/j.medcli.2022.02.013 [Article Type] Research article